Clinigen Group (LON:CLIN) Earns “Buy” Rating from Peel Hunt
Peel Hunt reissued their buy rating on shares of Clinigen Group (LON:CLIN) in a research note issued to investors on Thursday morning, ThisIsMoney.Co.Uk reports.
Separately, Peel Hunt reissued a buy rating and issued a GBX 1,390 ($18.16) target price on shares of Clinigen Group in a research note on Wednesday, June 26th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of GBX 1,371 ($17.91).
LON:CLIN opened at GBX 940 ($12.28) on Thursday. Clinigen Group has a 1-year low of GBX 716 ($9.36) and a 1-year high of GBX 1,069 ($13.97). The business’s 50-day moving average price is GBX 920.16 and its two-hundred day moving average price is GBX 963.69. The company has a current ratio of 1.54, a quick ratio of 1.32 and a debt-to-equity ratio of 56.71. The firm has a market capitalization of $1.26 billion and a price-to-earnings ratio of 47.24.
In other Clinigen Group news, insider Nick Keher purchased 3,900 shares of the stock in a transaction on Thursday, September 19th. The stock was bought at an average cost of GBX 893 ($11.67) per share, for a total transaction of £34,827 ($45,507.64).
Clinigen Group Company Profile
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Further Reading: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.